Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18389428 | 0.93 | P2RY14 (0.42) | P2RY14MCHR1ADORA3RIPK1ALOX5AP | |
| SCHEMBL18389327 | 0.90 | MAPT (0.39) | ADORA3RIPK1ALOX5APFEN1ALDH1A1 | |
| SCHEMBL20127047 | 0.89 | KDM4E (0.44) | P2RY14MCHR1ADORA3RIPK1ALOX5AP | |
| SCHEMBL20127046 | 0.89 | RIPK1 (0.38) | ADORA3RIPK1HDAC1KDM1AALDH1A1 | |
| SCHEMBL18389322 | 0.88 | CNR1 (0.43) | ADORA3RIPK1 | |
| SCHEMBL18389516 | 0.86 | P2RY14 (0.41) | P2RY14MCHR1ADORA3RIPK1ALOX5AP | |
| SCHEMBL20127045 | 0.86 | KMO (0.37) | RIPK1ALOX5APFEN1ALDH1A1KDM4C | |
| SCHEMBL18389521 | 0.86 | NPC1 (0.45) | ADORA3HDAC1KDM1AKDM4EALDH1A1 | |
| SCHEMBL21004125 | 0.86 | RIPK1 (0.36) | P2RY14RIPK1KDM4EALDH1A1HPGD | |
| SCHEMBL18389351 | 0.85 | EGLN1 (0.44) | RIPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709311-B | 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2020-09-25 | — | — | CN | claimed |
| EP-3322699-B1 | 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | claimed |
| CN-107709311-B | 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3322699-B1 | 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-20180125823-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180125823-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2017009274-A1 | 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125823-A1 | IMIDAZOLE DERIVATIVES | OXTR, DRD3, MC3R | P2RY14 3542/4885MCHR1 36/4885ADORA3 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.